Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma

ConclusionsTargeted therapy showed remarkable efficacy in ASC patients harboring sensitiveEGFR mutations, comparable to adenocarcinoma. The application of the third-generation TKI provided an option to prolong survival.
Source: Molecular Diagnosis and Therapy - Category: Molecular Biology Source Type: research